Over the past 12 months, 11 insiders at Roivant Sciences Ltd. filed 93 open-market SEC Form 4 transactions on ROIV: 1 purchase worth $50K and 92 sales worth $734.8M. Insiders have been net sellers over this period. The most recent filing was on Jun 30, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 26 | Meghan Fitzgerald | SELL | 10.0K | $34.90 | $349K |
| Jun 30, 26 | Daniel Allen Gold | SELL | 12.4K | $35.28 | $437K |
| Jun 29, 26 | Daniel Allen Gold | SELL | 600.0K | $34.59 | $20.8M |
| Jun 26, 26 | Daniel Allen Gold | SELL | 325.0K | $34.07 | $11.1M |
| Apr 16, 26 | Matthew GlineCEO | SELL | 289.8K | $29.16 | $8.4M |
| Mar 26, 26 | Meghan FitzgeraldDirector | SELL | 70.0K | $27.45 | $1.9M |
| Mar 17, 26 | Eric VenkerPresident & Immunovant CEO | SELL | 200.0K | $28.24 | $5.6M |
| Mar 16, 26 | Epperly Melissa BDirector | SELL | 41.9K | $28.68 | $1.2M |
| Feb 23, 26 | Frank TortiPresident and Vant Chair | SELL | 587.4K | $27.51 | $16.2M |
| Feb 20, 26 | Frank TortiPresident and Vant Chair | SELL | 1.01M | $27.15 | $27.5M |
| Feb 19, 26 | Frank TortiPresident and Vant Chair | SELL | 1.40M | $27.42 | $38.4M |
| Feb 13, 26 | Eric VenkerPresident & Immunovant CEO | SELL | 200.0K | $26.49 | $5.3M |
| Feb 13, 26 | Daniel Allen GoldDirector | SELL | 225.0K | $26.50 | $6.0M |
| Feb 13, 26 | Keith S ManchesterDirector | SELL | 225.0K | $26.50 | $6.0M |
| Feb 13, 26 | Qvt Financial LpOther | SELL | 225.0K | $26.50 | $6.0M |
| Feb 12, 26 | Daniel Allen GoldDirector | SELL | 275.0K | $26.76 | $7.4M |
| Feb 12, 26 | Keith S ManchesterDirector | SELL | 275.0K | $26.76 | $7.4M |
| Feb 12, 26 | Qvt Financial LpOther | SELL | 275.0K | $26.76 | $7.4M |
| Feb 11, 26 | Daniel Allen GoldDirector | SELL | 425.0K | $26.67 | $11.3M |
| Feb 11, 26 | Keith S ManchesterDirector | SELL | 425.0K | $26.67 | $11.3M |
| Feb 11, 26 | Qvt Financial LpOther | SELL | 425.0K | $26.67 | $11.3M |
| Feb 9, 26 | Mayukh SukhatmePresident & CIO | SELL | 339.4K | $26.47 | $9.0M |
| Jan 12, 26 | Eric VenkerPresident & Immunovant CEO | SELL | 200.0K | $21.92 | $4.4M |
| Dec 31, 25 | Mayukh SukhatmePresident & CIO | SELL | 1.02M | $21.71 | $22.1M |
| Dec 29, 25 | Mayukh SukhatmePresident & CIO | SELL | 311.9K | $21.74 | $6.8M |
| Dec 24, 25 | Eric VenkerPresident & Immunovant CEO | SELL | 75.0K | $22.53 | $1.7M |
| Dec 23, 25 | Richard PulikCFO | SELL | 260.0K | $22.45 | $5.8M |
| Dec 23, 25 | Eric VenkerPresident & Immunovant CEO | SELL | 200.0K | $22.45 | $4.5M |
| Dec 17, 25 | Mayukh SukhatmePresident & CIO | SELL | 26.8K | $23.09 | $620K |
| Dec 17, 25 | Daniel Allen GoldDirector | SELL | 432.7K | $23.17 | $10.0M |
| Dec 17, 25 | Keith S ManchesterDirector | SELL | 432.7K | $23.17 | $10.0M |
| Dec 17, 25 | Qvt Financial LpOther | SELL | 432.7K | $23.17 | $10.0M |
| Dec 16, 25 | Daniel Allen GoldDirector | SELL | 642.3K | $23.08 | $14.8M |
| Dec 16, 25 | Keith S ManchesterDirector | SELL | 642.3K | $23.08 | $14.8M |
| Dec 16, 25 | Qvt Financial LpOther | SELL | 642.3K | $23.08 | $14.8M |
| Dec 15, 25 | Matthew GlineCEO | SELL | 943.5K | $21.68 | $20.5M |
| Dec 15, 25 | Vivek RamaswamyTenPercentOwner | SELL | 353.7K | $22.05 | $7.8M |
| Dec 12, 25 | Vivek RamaswamyTenPercentOwner | SELL | 1.98M | $21.96 | $43.4M |
| Dec 11, 25 | Vivek RamaswamyTenPercentOwner | SELL | 774.1K | $21.64 | $16.8M |
| Dec 9, 25 | Eric VenkerPresident & Immunovant CEO | SELL | 200.0K | $20.85 | $4.2M |
| Nov 19, 25 | Daniel Allen GoldDirector | SELL | 850.0K | $20.25 | $17.2M |
| Nov 19, 25 | Keith S ManchesterDirector | SELL | 850.0K | $20.25 | $17.2M |
| Nov 19, 25 | Qvt Financial LpOther | SELL | 850.0K | $20.25 | $17.2M |
| Nov 17, 25 | Vivek RamaswamyTenPercentOwner | SELL | 539.6K | $20.51 | $11.1M |
| Nov 14, 25 | Vivek RamaswamyTenPercentOwner | SELL | 1.03M | $20.33 | $20.9M |
| Nov 13, 25 | Vivek RamaswamyTenPercentOwner | SELL | 287.3K | $20.81 | $6.0M |
| Nov 7, 25 | Eric VenkerPresident & Immunovant CEO | SELL | 200.0K | $20.22 | $4.0M |
| Oct 17, 25 | Eric VenkerPresident & Immunovant CEO | SELL | 118.4K | $17.06 | $2.0M |
| Oct 16, 25 | Eric VenkerPresident & Immunovant CEO | SELL | 318.3K | $17.05 | $5.4M |
| Oct 15, 25 | Eric VenkerPresident & Immunovant CEO | SELL | 414.7K | $16.93 | $7.0M |
Over the past 12 months, insiders at Roivant Sciences Ltd. filed 1 open-market purchase worth $50K and 92 sales worth $734.8M on ROIV, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 30, 26.
11 different insiders at Roivant Sciences Ltd. filed open-market SEC Form 4 transactions on ROIV over the last 12 months.
InsiderTape plots every ROIV insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Roivant Sciences Ltd. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →